BRAF and metastatic melanoma: Furthermore, it is worth considering that the therapeutic landscape of metastatic melanoma has been also improved by the availability of target therapy based on the combination of BRAF and MEK inhibitors in approximately 50% of patients carrying mutations in the amino acid V600 of the BRAF oncogene (14).